Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice.

Fröberg G, Jansson L, Bruchfeld J.

Eur Respir J. 2018 Nov 8. pii: 1801128. doi: 10.1183/13993003.01128-2018. [Epub ahead of print] No abstract available.

PMID:
30409821
2.

Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.

Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW.

J Infect. 2018 Oct 16. pii: S0163-4453(18)30307-4. doi: 10.1016/j.jinf.2018.10.004. [Epub ahead of print] Review.

PMID:
30339803
3.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

4.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
5.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2018 Aug 7. pii: S0163-4453(18)30246-9. doi: 10.1016/j.jinf.2018.08.003. [Epub ahead of print]

PMID:
30096332
6.

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May.

7.

Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study.

de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, Jacobsson LTH, Askling J; ARTIS Study Group.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1563-1567. doi: 10.1002/acr.23487. Epub 2018 Sep 4.

PMID:
29195024
8.

A borderline range for Quantiferon Gold In-Tube results.

Jonsson J, Westman A, Bruchfeld J, Sturegård E, Gaines H, Schön T.

PLoS One. 2017 Nov 2;12(11):e0187313. doi: 10.1371/journal.pone.0187313. eCollection 2017.

9.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

10.

Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points.

Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, Lange C.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637. doi: 10.5588/ijtld.16.0845. Review.

PMID:
28482956
11.

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.

Davies Forsman L, Bruchfeld J, Alffenaar JC.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700173. doi: 10.1183/13993003.00173-2017. Print 2017 Apr. No abstract available.

12.

Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?

Zuur MA, Akkerman OW, Davies Forsman L, Hu Y, Zheng R, Bruchfeld J, Tiberi S, Migliori GB, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1230-1233. doi: 10.1183/13993003.00833-2016. Epub 2016 Sep 1. No abstract available.

13.

Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice.

Hudson LK, Dancho ME, Li J, Bruchfeld JB, Ragab AA, He MM, Bragg M, Lenaghan D, Quinn MD, Fritz JR, Tanzi MV, Silverman HA, Hanes WM, Levine YA, Pavlov VA, Olofsson PS, Roth J, Al-Abed Y, Andersson U, Tracey KJ, Chavan SS.

Mol Med. 2016 Oct;22:585-596. doi: 10.2119/molmed.2016.00082. Epub 2016 Jun 10.

14.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

15.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
16.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

17.

A sensitive urinary lipoarabinomannan test for tuberculosis.

Hamasur B, Bruchfeld J, van Helden P, Källenius G, Svenson S.

PLoS One. 2015 Apr 23;10(4):e0123457. doi: 10.1371/journal.pone.0123457. eCollection 2015.

18.

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

19.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

20.

Tuberculosis and HIV Coinfection.

Bruchfeld J, Correia-Neves M, Källenius G.

Cold Spring Harb Perspect Med. 2015 Feb 26;5(7):a017871. doi: 10.1101/cshperspect.a017871. Review.

21.

Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.

Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET.

Am J Respir Crit Care Med. 2014 Nov 15;190(10):1168-76. doi: 10.1164/rccm.201405-0967OC.

PMID:
25303140
22.

Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Schön T, Simonsson US, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K.

Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22.

23.

Comparison between RFLP and MIRU-VNTR genotyping of Mycobacterium tuberculosis strains isolated in Stockholm 2009 to 2011.

Jonsson J, Hoffner S, Berggren I, Bruchfeld J, Ghebremichael S, Pennhag A, Groenheit R.

PLoS One. 2014 Apr 14;9(4):e95159. doi: 10.1371/journal.pone.0095159. eCollection 2014.

24.

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Jun;74(6):1212-7. doi: 10.1136/annrheumdis-2013-204960. Epub 2014 Mar 7.

PMID:
24608401
25.

Completing treatment for latent tuberculosis: patient background matters.

Kan B, Kalin M, Bruchfeld J.

Int J Tuberc Lung Dis. 2013 May;17(5):597-602. doi: 10.5588/ijtld.12.0692.

PMID:
23575323
26.

Extensive nosocomial transmission of tuberculosis in a low-incidence country.

Jonsson J, Kan B, Berggren I, Bruchfeld J.

J Hosp Infect. 2013 Apr;83(4):321-6. doi: 10.1016/j.jhin.2012.11.028. Epub 2013 Feb 21.

PMID:
23433580
27.

Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker.

Borgström E, Andersen P, Atterfelt F, Julander I, Källenius G, Maeurer M, Rosenkrands I, Widfeldt M, Bruchfeld J, Gaines H.

PLoS One. 2012;7(11):e43438. doi: 10.1371/journal.pone.0043438. Epub 2012 Nov 8.

28.

Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection.

Borgström E, Andersen P, Andersson L, Julander I, Källenius G, Maeurer M, Norrby M, Rosenkrands I, Tecleab T, Bruchfeld J, Gaines H.

J Immunol Methods. 2011 Jul 29;370(1-2):55-64. doi: 10.1016/j.jim.2011.05.008. Epub 2011 May 30.

PMID:
21641911
29.

A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis.

Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P; TBNET.

Tuberculosis (Edinb). 2011 May;91(3):260-7. doi: 10.1016/j.tube.2011.01.001. Epub 2011 Apr 2.

PMID:
21459676
30.

Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden.

Sandegren L, Groenheit R, Koivula T, Ghebremichael S, Advani A, Castro E, Pennhag A, Hoffner S, Mazurek J, Pawlowski A, Kan B, Bruchfeld J, Melefors Ö, Källenius G.

PLoS One. 2011 Jan 31;6(1):e16647. doi: 10.1371/journal.pone.0016647.

31.

Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection.

Houben RM, Crampin AC, Ndhlovu R, Sonnenberg P, Godfrey-Faussett P, Haas WH, Engelmann G, Lombard CJ, Wilkinson D, Bruchfeld J, Lockman S, Tappero J, Glynn JR.

Int J Tuberc Lung Dis. 2011 Jan;15(1):24-31. Review.

PMID:
21276292
32.

African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa.

Berg S, Garcia-Pelayo MC, Müller B, Hailu E, Asiimwe B, Kremer K, Dale J, Boniotti MB, Rodriguez S, Hilty M, Rigouts L, Firdessa R, Machado A, Mucavele C, Ngandolo BN, Bruchfeld J, Boschiroli L, Müller A, Sahraoui N, Pacciarini M, Cadmus S, Joloba M, van Soolingen D, Michel AL, Djønne B, Aranaz A, Zinsstag J, van Helden P, Portaels F, Kazwala R, Källenius G, Hewinson RG, Aseffa A, Gordon SV, Smith NH.

J Bacteriol. 2011 Feb;193(3):670-8. doi: 10.1128/JB.00750-10. Epub 2010 Nov 19. Erratum in: J Bacteriol. 2012 Mar;194(6):1641.

33.

Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden.

Ghebremichael S, Groenheit R, Pennhag A, Koivula T, Andersson E, Bruchfeld J, Hoffner S, Romanus V, Källenius G.

PLoS One. 2010 May 28;5(5):e10893. doi: 10.1371/journal.pone.0010893.

34.

Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden.

Kan B, Berggren I, Ghebremichael S, Bennet R, Bruchfeld J, Chryssanthou E, Källenius G, Petersson R, Petrini B, Romanus V, Sylvan S, Kalin M.

Int J Tuberc Lung Dis. 2008 Feb;12(2):199-204.

PMID:
18230254
35.

Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia.

Aderaye G, Bruchfeld J, Aseffa G, Nigussie Y, Melaku K, Woldeamanuel Y, Asrat D, Worku A, Gaegziabher H, Lebaad M, Lindquist L.

Scand J Infect Dis. 2007;39(11-12):1045-53. Epub 2007 Jul 2.

PMID:
17852928
36.
37.
38.

Occurrence of Pneumocystis carinii in HIV-positive patients with suspected pulmonary tuberculosis in Ethiopia.

Aderaye G, Bruchfeld J, Olsson M, Lindquist L.

AIDS. 2003 Feb 14;17(3):435-40.

PMID:
12556698
39.
40.

Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic and epidemiological characteristics.

Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke Y, Källenius G, Lindquist L.

Scand J Infect Dis. 2002;34(5):331-7.

PMID:
12069014
41.
42.

A controlled estimate of the risk of HIV infection in Ethiopian children with tuberculosis.

Berggren Palme I, Gudetta B, Degefu H, Muhe L, Bruchfeld J, Giesecke J.

Epidemiol Infect. 2001 Dec;127(3):517-25.

43.

Risk factors for human immunodeficiency virus infection in Ethiopian children with tuberculosis.

Palme IB, Gudetta B, Degefu H, Bruchfeld J, Muhe L, Giesecke J.

Pediatr Infect Dis J. 2001 Nov;20(11):1066-72. Erratum in: Pediatr Infect Dis J 2002 Jan;21(1):61.

PMID:
11734713
44.

Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine.

Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, Källenius G, Svenson SB.

J Microbiol Methods. 2001 May;45(1):41-52.

PMID:
11295196
45.

Sputum concentration improves diagnosis of tuberculosis in a setting with a high prevalence of HIV.

Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Källenius G, Lindquist L.

Trans R Soc Trop Med Hyg. 2000 Nov-Dec;94(6):677-80.

PMID:
11198655
46.

[Extrapulmonary tuberculosis--an infection of concern in most clinical settings].

Adamsson K, Bruchfeld J, Palme IB, Julander I.

Lakartidningen. 2000 Nov 29;97(48):5622-6. Swedish.

PMID:
11187379
47.

Skin concentrations of phenoxymethylpenicillin in patients with erysipelas.

Sjöblom AC, Bruchfeld J, Eriksson B, Jorup-Rönström C, Karkkonen K, Malmborg AS, Lindqvist M.

Infection. 1992 Jan-Feb;20(1):30-3.

PMID:
1563809
48.

Clearance of plasmodium falciparum after reduced single daily doses of quinine in asymptomatic children in Guinea Bissau.

Bruchfeld J, Dias F, Hellgren U, Lebbad M, Rombo L.

Trop Med Parasitol. 1991 Dec;42(4):386-8.

PMID:
1796238
49.

Low doses of quinine during a short time period are effective for clearance of Plasmodium falciparum in asymptomatic children in Guinea Bissau.

Bruchfeld J, Dias F, Hellgren U, Eriksson O, Andreasson PA, Crato J, Rombo L.

Trop Med Parasitol. 1991 Jun;42(2):153-4.

PMID:
1896775

Supplemental Content

Loading ...
Support Center